Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.